# Unified Risk Management Plan

<div align="center" style="margin-bottom: 20px;">

![Chimera Risk Management](https://img.shields.io/badge/-%F0%9F%A7%A0%20CHIMERA%20RISK%20MANAGEMENT%20%F0%9F%9B%A1-6236FF?style=for-the-badge&labelColor=1A1A2E)

[![ISO 14971](https://img.shields.io/badge/ISO%2014971-Compliant-blue?style=flat-square)](https://www.iso.org/standard/72704.html)
[![FDA](https://img.shields.io/badge/FDA-21%20CFR%20820-blue?style=flat-square)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=820)
[![CDSCO](https://img.shields.io/badge/CDSCO-MDR%202017-orange?style=flat-square)](https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/Medical-Device-Diagnostics/)
[![BIS](https://img.shields.io/badge/BIS-IS%2023485-green?style=flat-square)](https://www.bis.gov.in/)
[![Make in India](https://img.shields.io/badge/Make%20in%20India-Initiative-orange?style=flat-square)](https://www.makeinindia.com/)

</div>

## üìã Document Control

<table>
<tr>
<td width="33%">

### Document Details
**Document ID:** RM-PLAN-UNIFIED-001  
**Version:** 2.0.0  
**Status:** Approved

</td>
<td width="33%">

### Timeline
**Date Created:** April 10, 2025  
**Last Updated:** April 17, 2025  
**Review Cycle:** Annual

</td>
<td width="34%">

### Ownership
**Author:** Risk Management Team  
**Owner:** Risk Management Director  
**Reviewers:** CEO, CTO, Clinical Director

</td>
</tr>
<tr>
<td colspan="3">

### Revision History
**v1.0.0:** Initial version (April 10, 2025)  
**v2.0.0:** Enhanced version with integrated FDA and CDSCO requirements (April 17, 2025)

</td>
</tr>
</table>

## üéØ Purpose and Scope

<table>
<tr>
<td width="50%">

### Purpose
This Unified Risk Management Plan establishes a comprehensive framework for identifying, analyzing, evaluating, controlling, and monitoring risks associated with the Chimera neural interface system throughout its entire lifecycle. It integrates requirements from both US FDA and Indian CDSCO regulatory frameworks while adhering to international standards, particularly ISO 14971:2019.

</td>
<td width="50%">

### Scope
This plan applies to:
- All components of the Chimera neural interface system
- All phases of the product lifecycle from concept to post-market
- All geographical markets, with specific focus on US and Indian requirements
- All risk types including technical, clinical, usability, and cybersecurity risks

</td>
</tr>
</table>

## üåê Regulatory Framework

<div align="center">
<img src="https://mermaid.ink/img/pako:eNp1kk9PwzAMxb9KlBOI9QvkMG3qBBJiB8QOvUQmMY3WJlWSMjZV_e7YbVlhwJf4-fez_OzCuJUEBbwQb8lYvGvDLZIVUXxA8t5ZJA_WkVYRXdA6JGQvVkWUhLxGRWQMqQhXZJV3pCNcxHmcx1mcx_9i5_uoI1zGeZzHeZzH-b_YRYRXcR7ncR7ncR7nMXZ-jjrCdZzHeZzHeZzHeYyd36KO8C7O4zzO4zzO4zzGzh9RR_gY53Ee53Ee53EeY-fPqCP8ivM4j_M4j_M4j7HzLuoIf-I8zuM8zuM8zmPs_Bt1hMc4j_M4j_M4j_MYO0-ijvAU53Ee53Ee53EeY-c0wlOcx3mcx3mcx3mMnbMIT3Ee53Ee53Ee5zF2ziM8xXmcx3mcx3mcx9i5iPAU53Ee53Ee53EeY-cywnOcx3mcx3mcx3mMnasIz3Ee53Ee53Ee5zF2riO8xHmcx3mcx3mcx9i5ifAS53Ee53Ee53EeY-c2wkucx3mcx3mcx3mMnbsIL3Ee53Ee53Ee5zF27iO8xnmcx3mcx3mcx9h5iPAa53Ee53Ee53EeY-cxwmucx3mcx3mcx3mMnacIb3Ee53Ee53Ee5zF2niO8xXmcx3mcx3mcx9h5ifAW53Ee53Ee53EeY-c1wlucx3mcx3mcx3mMnbcI73Ee53Ee53Ee5zF23iO8x3mcx3mcx3mcx9j5iPAe53Ee53Ee53EeY-czwnucx3mcx3mcx3mMna8IH3Ee53Ee53Ee5zF2viN8xHmcx3mcx3mcx9j5ifAR53Ee53Ee53EeY-e_CB9xHudxHudxHucxdv4HxvXwKQ?type=png" alt="Regulatory Framework" width="700px" />
</div>

<table>
<tr>
<td width="33%">

### 2.1 International Standards
- **ISO 14971:2019**: Medical devices ‚Äî Application of risk management
- **ISO/TR 24971:2020**: Guidance on ISO 14971 application
- **IEC 62304:2015**: Medical device software lifecycle
- **IEC 62366-1:2015**: Medical device usability engineering
- **ISO 13485:2016**: Medical device quality management
- **ISO 27001:2022**: Information security management

</td>
<td width="33%">

### 2.2 US FDA Requirements
- **21 CFR Part 820**: Quality System Regulation
- **21 CFR Part 803**: Medical Device Reporting
- **21 CFR Part 806**: Reports of Corrections and Removals
- **FDA Guidance**: Benefit-Risk Determination
- **FDA Guidance**: Human Factors Engineering
- **FDA Guidance**: Cybersecurity in Medical Devices
- **FDA Guidance**: SaMD Clinical Evaluation

</td>
<td width="34%">

### 2.3 Indian CDSCO Requirements
- **Medical Device Rules, 2017** (as amended)
- **CDSCO Guidelines for SaMD**
- **Digital Personal Data Protection Act, 2023**
- **BIS IS 23485**: Medical device quality systems
- **CERT-In Guidelines** for cybersecurity
- **Make in India Initiative** requirements
- **ICMR Guidelines** for biomedical research

</td>
</tr>
</table>

## üë• Risk Management Organization

### 3.1 Risk Management Team

<table>
<tr>
<td width="50%">

#### Core Team
- **Risk Management Director**: Overall responsibility
- **Quality Assurance Representative**: QMS integration
- **Regulatory Affairs Representative**: Regulatory compliance
- **R&D Representative**: Technical expertise
- **Clinical Representative**: Clinical expertise
- **Human Factors Representative**: Usability expertise

</td>
<td width="50%">

#### Extended Team
- **Cybersecurity Specialist**: Security risk management
- **Manufacturing Representative**: Production risks
- **Service Representative**: Field service risks
- **Marketing Representative**: User needs
- **India Market Specialist**: India-specific requirements
- **US Market Specialist**: US-specific requirements

</td>
</tr>
</table>

### 3.2 Roles and Responsibilities

<table>
<tr>
<th>Role</th>
<th>Responsibilities</th>
</tr>
<tr>
<td>Risk Management Director</td>
<td>
- Overall responsibility for risk management process<br>
- Approval of risk management documentation<br>
- Reporting to executive management<br>
- Resource allocation for risk management activities
</td>
</tr>
<tr>
<td>Quality Assurance Representative</td>
<td>
- Integration with quality management system<br>
- Documentation control<br>
- Audit of risk management activities<br>
- Verification of risk control implementation
</td>
</tr>
<tr>
<td>Regulatory Affairs Representative</td>
<td>
- Ensuring compliance with regulatory requirements<br>
- Alignment with regulatory submissions<br>
- Monitoring regulatory changes<br>
- Market-specific regulatory requirements
</td>
</tr>
<tr>
<td>R&D Representative</td>
<td>
- Technical risk identification and analysis<br>
- Design of risk control measures<br>
- Implementation of design-related controls<br>
- Verification of technical risk controls
</td>
</tr>
<tr>
<td>Clinical Representative</td>
<td>
- Clinical risk identification and analysis<br>
- Clinical evaluation planning<br>
- Benefit-risk assessment<br>
- Clinical validation of risk controls
</td>
</tr>
<tr>
<td>India Market Specialist</td>
<td>
- India-specific risk identification<br>
- CDSCO compliance requirements<br>
- Indian infrastructure considerations<br>
- Cultural and regional adaptation
</td>
</tr>
</table>

## üîç Risk Management Process

<div align="center">
<img src="https://mermaid.ink/img/pako:eNp1kk9PwzAMxb9KlBOI9QvkMG3qBBJiB8QOvUQmMY3WJlWSMjZV_e7YbVlhwJf4-fez_OzCuJUEBbwQb8lYvGvDLZIVUXxA8t5ZJA_WkVYRXdA6JGQvVkWUhLxGRWQMqQhXZJV3pCNcxHmcx1mcx_9i5_uoI1zGeZzHeZzH-b_YRYRXcR7ncR7ncR7nMXZ-jjrCdZzHeZzHeZzHeYyd36KO8C7O4zzO4zzO4zzGzh9RR_gY53Ee53Ee53EeY-fPqCP8ivM4j_M4j_M4j7HzLuoIf-I8zuM8zuM8zmPs_Bt1hMc4j_M4j_M4j_MYO0-ijvAU53Ee53Ee53EeY-c0wlOcx3mcx3mcx3mMnbMIT3Ee53Ee53Ee5zF2ziM8xXmcx3mcx3mcx9i5iPAU53Ee53Ee53EeY-cywnOcx3mcx3mcx3mMnasIz3Ee53Ee53Ee5zF2riO8xHmcx3mcx3mcx9i5ifAS53Ee53Ee53EeY-c2wkucx3mcx3mcx3mMnbsIL3Ee53Ee53Ee5zF27iO8xnmcx3mcx3mcx9h5iPAa53Ee53Ee53EeY-cxwmucx3mcx3mcx3mMnacIb3Ee53Ee53Ee5zF2niO8xXmcx3mcx3mcx9h5ifAW53Ee53Ee53EeY-c1wlucx3mcx3mcx3mMnbcI73Ee53Ee53Ee5zF23iO8x3mcx3mcx3mcx9j5iPAe53Ee53Ee53EeY-czwnucx3mcx3mcx3mMna8IH3Ee53Ee53Ee5zF2viN8xHmcx3mcx3mcx9j5ifAR53Ee53Ee53EeY-e_CB9xHudxHudxHucxdv4HxvXwKQ?type=png" alt="Risk Management Process" width="700px" />
</div>

### 4.1 Risk Management Process Overview

The risk management process follows the ISO 14971:2019 framework with enhancements to address FDA and CDSCO requirements:

<table>
<tr>
<td width="50%">

1. **Risk Management Planning**:
   - Development of risk management plan
   - Resource allocation
   - Team formation
   - Process definition

2. **Risk Assessment**:
   - Hazard identification
   - Risk estimation
   - Risk evaluation
   - Benefit-risk analysis

</td>
<td width="50%">

3. **Risk Control**:
   - Risk control option analysis
   - Risk control implementation
   - Residual risk evaluation
   - Benefit-risk analysis

4. **Risk Management Review**:
   - Production and post-production information
   - Risk management report
   - Periodic review
   - Continuous improvement

</td>
</tr>
</table>

### 4.2 Risk Acceptance Criteria

<table>
<tr>
<th>Risk Level</th>
<th>Action Required</th>
<th>Approval Level</th>
</tr>
<tr>
<td>Very High</td>
<td>
- Must be eliminated or reduced to a lower level<br>
- Not acceptable under any circumstances<br>
- Product cannot proceed with Very High risks
</td>
<td>CEO, CTO, Clinical Director, Quality Director, Regulatory Affairs Director</td>
</tr>
<tr>
<td>High</td>
<td>
- Must be reduced to Medium or Low level<br>
- If reduction not possible, detailed benefit-risk analysis required<br>
- Extensive justification and executive approval required
</td>
<td>CTO, Clinical Director, Quality Director, Regulatory Affairs Director</td>
</tr>
<tr>
<td>Medium</td>
<td>
- Should be reduced to Low level where feasible<br>
- If not reduced, benefit-risk analysis required<br>
- Monitoring controls must be implemented
</td>
<td>Quality Director, Risk Management Director</td>
</tr>
<tr>
<td>Low</td>
<td>
- Generally acceptable with standard controls<br>
- Monitoring through normal quality processes<br>
- No special approval required
</td>
<td>Risk Management Director</td>
</tr>
</table>

### 4.3 Risk Estimation Matrix

<div align="center">

<table>
<tr>
<th colspan="6">Risk Estimation Matrix</th>
</tr>
<tr>
<th rowspan="6" style="writing-mode: vertical-rl; text-orientation: mixed;">Severity</th>
<th>Catastrophic (5)</th>
<td bgcolor="#FF0000">Very High</td>
<td bgcolor="#FF0000">Very High</td>
<td bgcolor="#FF0000">Very High</td>
<td bgcolor="#FF0000">Very High</td>
<td bgcolor="#FF0000">Very High</td>
</tr>
<tr>
<th>Critical (4)</th>
<td bgcolor="#FFA500">High</td>
<td bgcolor="#FF0000">Very High</td>
<td bgcolor="#FF0000">Very High</td>
<td bgcolor="#FF0000">Very High</td>
<td bgcolor="#FF0000">Very High</td>
</tr>
<tr>
<th>Serious (3)</th>
<td bgcolor="#FFFF00">Medium</td>
<td bgcolor="#FFA500">High</td>
<td bgcolor="#FF0000">Very High</td>
<td bgcolor="#FF0000">Very High</td>
<td bgcolor="#FF0000">Very High</td>
</tr>
<tr>
<th>Minor (2)</th>
<td bgcolor="#00FF00">Low</td>
<td bgcolor="#FFFF00">Medium</td>
<td bgcolor="#FFA500">High</td>
<td bgcolor="#FF0000">Very High</td>
<td bgcolor="#FF0000">Very High</td>
</tr>
<tr>
<th>Negligible (1)</th>
<td bgcolor="#00FF00">Low</td>
<td bgcolor="#00FF00">Low</td>
<td bgcolor="#FFFF00">Medium</td>
<td bgcolor="#FFA500">High</td>
<td bgcolor="#FF0000">Very High</td>
</tr>
<tr>
<th></th>
<th>Remote (1)</th>
<th>Unlikely (2)</th>
<th>Occasional (3)</th>
<th>Probable (4)</th>
<th>Frequent (5)</th>
</tr>
<tr>
<th colspan="7">Probability</th>
</tr>
</table>

</div>

### 4.4 Severity Classification

<table>
<tr>
<th>Level</th>
<th>Category</th>
<th>Description</th>
<th>Examples</th>
</tr>
<tr>
<td>5</td>
<td>Catastrophic</td>
<td>Results in patient death</td>
<td>
- Fatal electric shock<br>
- Fatal fall due to device malfunction<br>
- Fatal brain injury
</td>
</tr>
<tr>
<td>4</td>
<td>Critical</td>
<td>Results in permanent impairment or life-threatening injury</td>
<td>
- Permanent neurological damage<br>
- Severe burns requiring surgery<br>
- Permanent loss of function
</td>
</tr>
<tr>
<td>3</td>
<td>Serious</td>
<td>Results in injury or impairment requiring professional medical intervention</td>
<td>
- Fractures from falls<br>
- Moderate burns<br>
- Temporary neurological effects
</td>
</tr>
<tr>
<td>2</td>
<td>Minor</td>
<td>Results in temporary injury or impairment not requiring professional medical intervention</td>
<td>
- Minor bruising<br>
- Skin irritation<br>
- Temporary discomfort
</td>
</tr>
<tr>
<td>1</td>
<td>Negligible</td>
<td>Inconvenience or temporary discomfort</td>
<td>
- Momentary discomfort<br>
- Delayed therapy<br>
- Minor operational issues
</td>
</tr>
</table>

### 4.5 Probability Classification

<table>
<tr>
<th>Level</th>
<th>Category</th>
<th>Description</th>
<th>Quantitative Definition</th>
</tr>
<tr>
<td>5</td>
<td>Frequent</td>
<td>Likely to occur often</td>
<td>More than once per 1,000 uses</td>
</tr>
<tr>
<td>4</td>
<td>Probable</td>
<td>Likely to occur several times</td>
<td>Once per 1,000 to 10,000 uses</td>
</tr>
<tr>
<td>3</td>
<td>Occasional</td>
<td>Likely to occur sometime</td>
<td>Once per 10,000 to 100,000 uses</td>
</tr>
<tr>
<td>2</td>
<td>Unlikely</td>
<td>Unlikely but possible to occur</td>
<td>Once per 100,000 to 1,000,000 uses</td>
</tr>
<tr>
<td>1</td>
<td>Remote</td>
<td>So unlikely that it can be assumed occurrence may not be experienced</td>
<td>Less than once per 1,000,000 uses</td>
</tr>
</table>

## üõ°Ô∏è Risk Control Process

### 5.1 Risk Control Option Hierarchy

<table>
<tr>
<td width="50%">

Risk control options are considered in the following priority order:

1. **Inherent Safety by Design**:
   - Elimination of hazards through design changes
   - Reduction of severity or probability through design features
   - Architectural safety features

2. **Protective Measures**:
   - Safety mechanisms
   - Alarms and warnings
   - Automatic safeguards
   - Redundant systems

</td>
<td width="50%">

3. **Information for Safety**:
   - Warnings and cautions
   - Restrictions on use
   - Training requirements
   - Procedural controls

4. **Organizational Measures**:
   - Quality control procedures
   - Preventive maintenance
   - Calibration requirements
   - Service procedures

</td>
</tr>
</table>

### 5.2 Risk Control Implementation Process

<div align="center">
<img src="https://mermaid.ink/img/pako:eNp1kk9PwzAMxb9KlBOI9QvkMG3qBBJiB8QOvUQmMY3WJlWSMjZV_e7YbVlhwJf4-fez_OzCuJUEBbwQb8lYvGvDLZIVUXxA8t5ZJA_WkVYRXdA6JGQvVkWUhLxGRWQMqQhXZJV3pCNcxHmcx1mcx_9i5_uoI1zGeZzHeZzH-b_YRYRXcR7ncR7ncR7nMXZ-jjrCdZzHeZzHeZzHeYyd36KO8C7O4zzO4zzO4zzGzh9RR_gY53Ee53Ee53EeY-fPqCP8ivM4j_M4j_M4j7HzLuoIf-I8zuM8zuM8zmPs_Bt1hMc4j_M4j_M4j_MYO0-ijvAU53Ee53Ee53EeY-c0wlOcx3mcx3mcx3mMnbMIT3Ee53Ee53Ee5zF2ziM8xXmcx3mcx3mcx9i5iPAU53Ee53Ee53EeY-cywnOcx3mcx3mcx3mMnasIz3Ee53Ee53Ee5zF2riO8xHmcx3mcx3mcx9i5ifAS53Ee53Ee53EeY-c2wkucx3mcx3mcx3mMnbsIL3Ee53Ee53Ee5zF27iO8xnmcx3mcx3mcx9h5iPAa53Ee53Ee53EeY-cxwmucx3mcx3mcx3mMnacIb3Ee53Ee53Ee5zF2niO8xXmcx3mcx3mcx9h5ifAW53Ee53Ee53EeY-c1wlucx3mcx3mcx3mMnbcI73Ee53Ee53Ee5zF23iO8x3mcx3mcx3mcx9j5iPAe53Ee53Ee53EeY-czwnucx3mcx3mcx3mMna8IH3Ee53Ee53Ee5zF2viN8xHmcx3mcx3mcx9j5ifAR53Ee53Ee53EeY-e_CB9xHudxHudxHucxdv4HxvXwKQ?type=png" alt="Risk Control Process" width="700px" />
</div>

<table>
<tr>
<td width="50%">

1. **Risk Control Option Analysis**:
   - Identification of potential risk control options
   - Evaluation of feasibility and effectiveness
   - Selection of appropriate risk control measures

2. **Risk Control Implementation**:
   - Implementation of selected risk control measures
   - Documentation of implementation details
   - Traceability to identified risks

</td>
<td width="50%">

3. **Residual Risk Evaluation**:
   - Evaluation of risk after implementation of controls
   - Determination of residual risk acceptability
   - Identification of additional control needs

4. **Risk-Benefit Analysis**:
   - Evaluation of overall residual risk
   - Comparison with medical benefits
   - Determination of overall risk acceptability

</td>
</tr>
</table>

### 5.3 Risk Control Verification Methods

<table>
<tr>
<td width="50%">

The following methods are used to verify risk control effectiveness:

1. **Design Verification**:
   - Testing against specifications
(Content truncated due to size limit. Use line ranges to read in chunks)
